Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
Br J Cancer
; 119(9): 1052-1059, 2018 10.
Article
in En
| MEDLINE
| ID: mdl-30131546
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Dexamethasone
/
Prednisone
/
Antineoplastic Agents, Hormonal
/
Prostatic Neoplasms, Castration-Resistant
Type of study:
Clinical_trials
/
Observational_studies
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Br J Cancer
Year:
2018
Document type:
Article
Affiliation country:
Country of publication: